01:35 AM EDT, 05/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $65 from $60, based on our DCF model. We up our 2025 EPS estimate to $0.21 from $0.05. We keep our 2026 EPS estimate at $1.29. We are seeing a solid market reaction today with EXAS shares up 11% D/D after the company reported robust Q1 results. Q1 revenue grew a solid 11% Y/Y, driven by strong performance in the Screening segment. The company's flagship Cologuard test continued to gain traction, contributing to a 14% Y/Y increase in Screening revenue, reaching $540M. EXAS also made progress on its key strategic initiatives during the quarter, in our view, launching two innovative tests. The Cologuard Plus test, an enhanced or next generation version of the original Cologuard, offers improved sensitivity and specificity for colon cancer screening. Additionally, EXAS introduced the Oncodetect test, expanding its presence in the precision oncology market. For 2025, we expect this strong momentum to continue and see sales rising a solid 10.4% Y/Y.